At a glance
ClinicalIndex Comparison RecordN/ACompleted· 6 enrolled
Drug / intervention
Technetium-99m macroaggregated albumin (Tc-99m MAA)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
TheraSphere Post-approval Study to Calculate the Radiation-absorbed Dose of Technetium-99m Macroaggregated Albumin (Tc-99m MAA) to the Whole Body and Non-liver Critical Organs.
In Brief
An observational study evaluating Technetium-99m macroaggregated albumin (Tc-99m MAA) for Hepatocellular Carcinoma. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The TheraSphere Post-Approval Study is a post-market, prospective, single-arm, open-label, observational study to support the use of TheraSphere for the treatment of hepatocellular carcinoma (HCC).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20222023202420252026
First PostedFeb 2022
Enrollment StartApr 2022
Primary CompletionJun 2023
TodayJul 2026
First PostedFeb 10, 2022
Enrollment StartApr 4, 2022
Primary CompletionJun 14, 2023
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 4.4 years ago
Interventions
Technetium-99m macroaggregated albumin (Tc-99m MAA)device
Patients who are being evaluated for TheraSphere administration.